New trial finds single dose of LSD-based therapy led to anxiety relief for many patients
-
A clinical trial found a single dose of MM120 (a formulation of LSD) led to a 48% remission rate from generalized anxiety disorder symptoms after 12 weeks
-
MM120 received FDA breakthrough therapy status, meaning it demonstrated evidence of effectiveness for a serious condition and may speed up development
-
The phase 2b trial found MM120 improved anxiety symptoms for 65% of participants within 3 months
-
Unlike other psychedelic therapy trials, MM120 did not require psychotherapy during the dosing session to achieve benefits
-
This is the first medical study of LSD for mental health treatment in over 40 years, since research was halted due to LSD becoming illegal